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Abstract: 
How pancreatic ductal adenocarcinoma (PDA) cells stimulate CXCR4 to exclude T cells and 
resist T cell checkpoint inhibitors is not known.  Here, we find that CXCL12, the ligand for 
CXCR4 that is produced by the cancer-associated fibroblast, “coats” human PDA and colorectal 
cancer cells as covalent heterodimers with keratin 19 (KRT19).  Modeling the formation of the 25 
heterodimer with three proteins shows that KRT19 binds CXCL12 and transglutaminase-2 
(TGM2), and that TGM2 converts the reversible KRT19-CXCL12 complex into a covalent 
heterodimer.  We validate this model by showing that cancer cells in mouse PDA tumors must 
express KRT19 and TGM2 to become coated with CXCL12, exclude T cells, and resist 
immunotherapy with anti-PD-1 antibody.  Thus, PDA cells have a cell-autonomous means by 30 
which they capture CXCL12 to mediate immune suppression, which is potentially amenable to 
therapy. 
One Sentence Summary: 
Cancer cells in pancreatic ductal adenocarcinoma use transglutaminase-2 to assemble a coating 
comprised of covalent CXCL12-keratin 19 heterodimers that excludes T cells and mediates 35 
resistance to inhibition of the PD-1 T cell checkpoint. 
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The major challenge in cancer immunology is to define the molecular pathway by which 
adenocarcinomas exclude T cells and resist immunotherapy with inhibitors of T cell checkpoints 
(1).  An early clue to the identity of this pathway was the finding that depleting the cancer-
associated fibroblast (CAF) in an autochthonous mouse model of PDA slowed tumor growth and 5 
uncovered sensitivity to the anti-tumor effects of anti-PD-L1 antibody (2).  The immune 
suppressive function of the CAF was traced to its production of the chemokine, CXCL12, when 
treatment of PDA-bearing mice with AMD3100, a small molecule inhibitor of CXCR4, the 
receptor for CXCL12, overcame the exclusion of T cells by cancer cell nests, and uncovered the 
anti-tumor activity of anti-PD-L1 antibody.  The capacity of CXCR4 that has been stimulated by 10 
CXCL12 to suppress the intra-tumoral accumulation of T cells may be related to its inhibition of 
the chemotactic function of CXCR3 (3).  Two recent early stage clinical studies of CXCR4 
inhibition in patients with metastatic PDA have confirmed the clinical relevance of these pre-
clinical observations (3, 4). 
Since CXCR4 signaling accounts for the non-random distribution of intra-tumoral T cells 15 
away from cancer cells and into the stroma, we determined whether CXCL12 also was present in 
a non-random, but opposite, distribution in human PDA and other carcinomas.  We stained 
sections of freshly resected human PDA and colorectal cancer (CRC) with fluorochrome- 
conjugated antibodies to KRT19, which would identify cancer cells, and to CXCL12.  Confocal 
microscopy showed that only the KRT19+ cancer cells demonstrated binding of the anti-20 
CXCL12 antibody (Fig. 1A).  This restricted distribution of CXCL12 to cancer cells was 
observed in seven additional types of human carcinomas (fig. S1A and B).  Human melanoma, 
which is a non-epithelial cancer that does not express KRT19, did not bind anti-CXCL12 
antibody.    
To determine how CXCL12 associates with cancer cells in PDA and CRC, we 25 
sequentially eluted samples of the human PDA and CRC tumors with buffers containing NP-40 
and SDS, respectively, and analyzed the eluted proteins by SDS-PAGE followed by 
immunoblotting with anti-CXCL12 and anti-KRT19 antibodies.  CXCL12, despite being a 
soluble protein that is secreted by CAFs, was detected only in the SDS-eluates (Fig. 1B and fig. 
S1C).  Moreover, the eluted CXCL12 appeared with a relative molecular weight of ~55 kD 30 
instead of the nominal 10-13 kD molecular weights of its isoforms.  KRT19, as expected for an 
intermediate filament protein, also required SDS for solubilization, and presented with its 
predicted molecular weight of ~45 kD, and two higher molecular weight forms, one of which 
corresponded to the molecular weight of the eluted CXCL12 (Fig. 1B).  Examination of the 
immunoprecipitate obtained with anti-CXCL12 antibody from the combined SDS-eluates of the 35 
four tumors revealed that this high molecular weight form of KRT19 co-immunoprecipitated 
with anti-CXCL12, indicating the occurrence of a CXCL12-KRT19 heterodimer (Fig. 1C).  
Mouse PDA, in which KRT19+ cancer cells also stain with fluorochrome-conjugated anti-
CXCL12 antibody (fig. S2A), also demonstrated the presence of an SDS-soluble, CXCL12-
KRT19 heterodimer (fig. S2B and C).  Thus, all CXCL12 that could be detected in the SDS-40 
eluates of human PDA and CRC and mouse PDA was present in a stable, apparently covalent, 
heterodimer with KRT19. 
Confirming a previous finding (2), Cxcl12 mRNA was detected in mouse PDA tumors 
mainly in CAFs expressing Pdgfra mRNA (fig. S2D).  Individual cancer cells in non-
permeabilized sections could be stained with antibodies specific for CXCL12 and KRT19, 45 
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respectively (fig S2E).  Also, analysis by flow cytometry of intact single cells from mouse PDA 
tumors that had been stained with anti-CXCL12 and anti-KRT19 antibodies showed that all 
CXCL12+ cells were KRT19+ (fig. S2F).  Thus, cancer cells are capable of secreting the 
intermediate filament protein, KRT19, as has been previously reported (5), to participate in the 
formation of a CXCL12-KRT19 heterodimer.   5 
We modeled the formation of the CXCL12-KRT19 complex by reasoning that a non-
covalent interaction between KRT19 and CXCL12 is stabilized by an enzyme capable of 
crosslinking proteins, such as TGM2, which is expressed by both PDA and CRC cancer cells (6, 
7).  Streptavidin beads bearing C-terminally biotinylated human CXCL12 were incubated with 
increasing concentrations of KRT19, and bound KRT19 was measured by SDS-PAGE and 10 
immunoblotting with anti-KRT19 antibody.  CXCL12 bound KRT19 in a saturable manner with 
a nanomolar affinity (Fig. 1D and fig. S3A).  As a negative control, KRT19 did not interact with 
another chemokine, CXCL8 (fig. S3B).  Formation of a trimolecular complex was then assessed 
by incubating beads bearing KRT19 at 4°C with CXCL12 and TGM2 in the presence or absence 
of Ca2+. KRT19 bound CXCL12 regardless of the presence of Ca2+, but binding of TGM2 15 
required the cation, suggesting that the open conformation of TGM2 was required for this 
interaction (Fig. 1E).  Beads bearing biotinylated CXCL12 only bound TGM2 in the presence of 
KRT19 and Ca2+, confirming the Ca2+-dependence of the interaction between KRT19 and TGM2 
(fig. S3C).  Preformed CXCL12-KRT19 complexes were incubated with TGM2 at 20°C in the 
presence of Ca2+, and with or without ERW1041E, an inhibitor of the TGM2 transamidase site 20 
(8).  TGM2 generated a heterodimeric complex of ~55kD containing CXCL12 and KRT19, 
similar to complex that was eluted from PDA and CRC, and its formation was blocked by 
ERW1041E (Fig. 1F).  An additional, higher molecular form of CXCL12 and KRT19 was also 
generated that was not observed in the SDS-eluates of tumors, perhaps indicating that that SDS 
does not solubilize all CXCL12-containing complexes from tumors.  Including ERW1041E 25 
during the detergent elution of mouse PDA tumors did not diminish recovery of the high 
molecular weight form of CXCL12, excluding a possibility that the complex was generated in 
vitro (fig. S3D).  Thus, KRT19 has two independent sites that mediate the binding of CXCL12 
and of TGM2 in its Ca2+-induced, catalytically active open conformation (9).  This trimolecular 
interaction may facilitate the formation of the CXCL12-KRT19 coating of cancer cells.   30 
To test the prediction that TGM2 is required for the formation of the CXCL12-KRT19 
coating in vivo, we generated subcutaneous tumors with control PDA cells or PDA cells in which 
the Tgm2 gene had been edited (fig. S4), in wild type mice or mice in which the Tgm2 gene had 
been interrupted (10).  Analysis of tumor sections revealed that loss of TGM2 from cancer cells, 
but not from the host, greatly diminished both the staining of cancer cells with anti-CXCL12 35 
antibody (Fig. 2A), and the amount of the SDS-soluble, high molecular weight form of CXCL12 
(fig. S5A).  The residual high molecular weight CXCL12 may have been generated by FXIIIa, a 
transglutaminase that is expressed by macrophages and was detected by immunofluorescence 
(fig. S5B), but not by other members of the transglutaminase family, which are not expressed by 
mouse PDA cells (fig.S5C) (11).  T cells accumulated in areas of the tumors in which CXCL12 40 
was absent, and there was T cell-dependent slowing of tumor growth that was accompanied by 
elevated mRNA levels of genes characteristic of cytotoxic CD8+ T cells (Fig. 2B-D).  Despite 
the presence of host-derived TGM2 in the stroma of PDA tumors (fig. S5D), this TGM2 did not 
compensate for loss of cancer cell TGM2 in the coating of cancer cells with CXCL12, nor affect 
tumor growth (Fig. 2C).  Thus, TGM2 from the cancer cells has an essential role in formation of 45 
the CXCL12-KRT19 coating. 
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An indispensable role for KRT19 was demonstrated by the absence of the CXCL12-
KRT19 coating on PDA cells in which the Krt19 gene had been edited (Fig. 3A and fig. S6A-C). 
These tumors also were infiltrated with T cells, exhibited T cell-dependent, slower growth, and 
had elevated mRNA levels of immunologically relevant genes (Fig. 3A-C).  In contrast, 
interrupting the expression of KRT18 in PDA cells did not diminish the staining of tumors with 5 
anti-CXCL12 antibody (fig. S6D).  Rescue of KRT19 expression in the PDA cells reversed these 
phenotypic changes (fig. S7).  Therefore, we conclude that the CXCL12-KRT19 heterodimer 
mediates T cell exclusion and immune suppression, since blocking its formation by interrupting 
the expression of two unrelated genes, Tgm2 and Krt19, results in the same immunological 
outcome. 10 
T cells accumulate in cancer cell nests in microsatellite instable (MSI) PDA (12), yet the 
CXCL12-KRT19 coating is maintained (fig. S8A, B), suggesting either that this cancer 
represents an exception to the immune suppressive function of the CXCL12-KRT19 coating, or 
that the increased immunogenicity of MSI PDA is an independent determinant of the intra-
tumoral immune reaction.  To distinguish between these possibilities, we formed hepatic 15 
metastases and subcutaneous tumors containing mouse PDA cells expressing the foreign antigen, 
ovalbumin (OVA).  The OVA-expressing hepatic metastases were infiltrated with OVA-specific 
CD8+ T cells (fig. S8C), reproducing this characteristic of MSI PDA.  In subcutaneous tumors, 
expression of OVA or loss of KRT19 equivalently slowed tumor growth, and led to the increased 
expression of the same set of immune-related genes (Fig. 3D and E).  Combining OVA 20 
expression with the absence of KRT19 expression further decreased PDA growth so that 4/5 
tumors were eliminated by day 30.  Thus, immune suppression by the CXCL12-KRT19 coating 
is maintained in a highly immunogenic PDA tumor, and immunogenicity and the CXCL12-
KRT19 coating are independent determinants of the intra-tumoral immune reaction. 
A role for the CXCL12-KRT19 coating in the resistance of mouse PDA to inhibition of 25 
the PD-1 T cell checkpoint was assessed. Subcutaneous tumors were formed with control PDA 
cells or cells that did not express either KRT19 or TGM2.  Treatment with rat anti-PD-1 IgG or 
non-immune IgG was initiated on day 13 when all PDA tumors were established.  The 
administration of these rat antibodies was limited to one week, after which mouse anti-rat IgG 
antibodies develop (fig. S9).  The growth rate of tumors containing control PDA cells was not 30 
altered by the administration of the anti-PD-1 antibody, and the experiment was terminated on 
day 17 when tumors had attained a pre-determined size limit (Fig. 4A).  Tumors comprised of 
PDA cells lacking expression of either KRT19 or TGM2 grew more slowly than those formed 
with control PDA cells, and responded to anti-PD-1 antibody with diminished growth rates (Fig. 
4A) and increased transcription of genes expressed by effector CD8+ T cells (fig. S10).  Hepatic 35 
metastases formed with luciferase-expressing control PDA cells exhibited staining with anti-
CXCL12 antibody and excluded T cells, whereas those formed with KRT19-deficient PDA cells 
lacked the CXCL12-KRT19 coating and were infiltrated with T cells, despite containing 
CXCL12-expressing CAFs (fig. S11).  Treatment with anti-PD-1 antibody did not alter the 
growth rates of KRT19-expressing tumors, whereas it arrested the growth of metastases 40 
containing PDA cells not expressing KRT19 (Fig. 4B and fig. S12), and increased the expression 
of genes indicating the presence of effector CD8+ T cells (fig. S13). 
Taken together, these studies show that there is a cancer cell-autonomous mechanism 
involving KRT19 and TGM2 for capturing CXCL12, the mediator of immune suppression by 
CAFs.  The resulting CXCL12-KRT19 coating explains the capacity of cancer cells to exclude T 45 
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cells and to resist inhibitors of the PD-1 checkpoint.  The finding that KRT19 interacts with 
CXCL12 and TGM2 to assemble the CXCL12-KRT19 coating offers new approaches to cancer 
immunotherapy.  
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Figure 1: The CXCL12-KRT19 coating of cancer cells. (A) Sections of freshly resected 
human PDA and CRC were stained with fluorochrome-conjugated antibodies to KRT19 and 
CXCL12. Scale bar, 100 µm. (B) SDS-eluates of samples of the resected PDA and CRC were 
subjected to SDS-PAGE and immunoblotting with antibodies to CXCL12 and KRT19. (C) The 5 
proteins that were immunoprecipitated by control IgG or anti-CXCL12 IgG from the pooled 
SDS-eluates of the four tumors were subjected to SDS-PAGE and immunoblotting with anti- 
CXCL12 and anti-KRT19 antibodies. (D) Streptavidin-beads bearing CXCL12-biotin were 
incubated with increasing concentrations of KRT19. Bound KRT19 was detected by SDS-PAGE 
and immunoblotting with anti-KRT19 antibody. The apparent affinity with which CXCL12 and 10 
KRT19 interacted was calculated. (E) Anti-KRT19 antibody/protein G beads were incubated at 
4°C with combinations of KRT19, CXCL12 and TGM2, in the presence or absence of Ca2+. The 
bound proteins were detected by SDS-PAGE and immunoblotting with the indicated antibodies. 
(F) Streptavidin beads bearing preformed complexes of biotinylated CXCL12 and KRT19 were 
incubated at 20°C for 15 min with TGM2 in the presence or absence of the TGM2 inhibitor, 15 
ERW1041E. The proteins were eluted from the beads and detected by SDS-PAGE and 
immunoblotting with antibodies to CXCL12 and KRT19. 
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Figure 2: The role of TGM2 expressed by PDA cells in the formation of the CXCL12- 
KRT19 coating. sgScramble or sgTGM2-edited PDA cells were inoculated subcutaneously in 
wild-type hosts or TGM2-deficient hosts.  (A) Cross sections of the entire tumors of each type 
were stained with fluorochrome-conjugated antibodies to KRT19 and CXCL12.  Representative 5 
images are shown. Scale bars, 1 mm. (B) Sections of each of the four tumor types were stained 
with fluorochrome-conjugated antibodies to KRT19, CXCL12, and CD3. Representative images 
are shown.  Scale bars, 100 µm. (C) The growth curves of each of the four tumor types in panel 
B are shown. n=5. (D) The growth curves are shown of tumors formed with sgScramble PDA 
cells and sgTGM2-edited PDA cells, respectively, in wild-type hosts that were untreated, or 10 
treated with non-immune IgG or the T cell depleting antibodies to CD4 and CD8. n=5. (E) The 
mRNA levels of immune genes in tumors formed with sgTGM2-edited PDA cells in wild-type 
hosts were compared to those of tumors formed with sgScramble PDA cells. Mean ± SEM; ns, 
not significant, ** p<0.01, *** p<0.001, Student’s t test.  
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Figure 3: The role of KRT19 expressed by PDA cells in the formation of the CXCL12- 
KRT19 coating. (A) Sections of subcutaneous tumors formed with sgScramble control PDA 
cells and sgKRT19-edited PDA cells were stained with fluorochrome-conjugated antibodies to 
KRT19, KRT20, CXCL12 and CD3. Scale bars, 100 µm. (B) The growth curves are shown of 5 
subcutaneous tumors formed with sgScramble PDA cells and sgKRT19-edited PDA cells in mice 
that were untreated or treated with either non-immune IgG or T cell-depleting antibodies to CD4 
and CD8. n=5. (C) The mRNA levels of immune genes in tumors formed with sgKRT19-edited 
PDA cells are compared to those of tumors formed with sgScramble PDA cells. (D) The growth 
curves are shown of subcutaneous tumors formed with sgScramble PDA cells or sgKRT19-10 
edited PDA cells that had been engineered to express doxycycline (Dox)-inducible cytoplasmic 
OVA (icOVA) in mice fed normal food (-Dox) or food containing Dox (+Dox). Mean ± SEM; 
n=5. ns, not significant, *, p<0.05, ** p<0.01, *** p<0.001. Paired t test. (E) The heat map is 
shown of the relative levels of expression of immune genes as detected by RNA-Seq assay of 
individual subcutaneous tumors formed with sgScramble PDA cells, OVA-expressing 15 
sgScramble PDA cells, and sgKRT19-edited PDA cells, respectively. 
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Figure 4: Treatment of mice bearing PDA tumors with antibody to PD-1. (A) Mice bearing 
subcutaneous tumors formed with sgScramble control PDA cells, sgKRT19-edited PDA cells, or 
sgTGM2-edited PDA cells were treated by intra-peritoneal administration of non-immune IgG or 
anti-PD-1 IgG (arrows), and tumor growth was measured. (B) Mice bearing hepatic metastases 5 
formed with luciferase-expressing sgScramble control PDA cells or sgKRT19-edited PDA cells 
were treated with non-immune IgG or anti-PD-1 IgG (arrows), and growth of the metastases was 
measured by bioluminescent imaging. 
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Materials and Methods 
Human Tumor Samples 
All human tumor samples used in this study are approved by institutions’ Institutional Review 
Board (IRB). Freshly resected human pancreas and colon tumors were obtained from Northwell 
Health Tissue Donation Program. The collected tumor samples were temporarily stored in RPMI 
medium and delivered on ice the same day of surgical removal. After receiving, part of each 
sample was embedded in Tissue-Tek OCT compound (Sakura, 4583) for immunofluorescence 
staining and the rest was flash-frozen in liquid nitrogen for protein extraction. Formalin fixed 
paraffin embedded (FFPE) human tumor arrays for pancreas cancer (PA501a), colon cancer 
(BC05021a), breast cancer (BC08013c), bladder cancer (BC12011d), melanoma (ME483a) and 
frozen multiple organ tumor/tissue arrays (FMC282e and FMO401) were purchased from US 
Biomax.  
Tumor Protein Extraction 
Tumor pieces of about 100 mg were used for protein extraction. Freshly dissected tumor pieces 
or the tumor pieces that were previously flash-frozen in liquid nitrogen and subsequently stored 
at -80°C were briefly homogenized in 1 ml ice cold IP buffer (75 mM HEPES, pH 7.5, 150 mM 
NaCl, 1 mM DTT, 10% Glycerol and protease inhibitor cocktail (Thermo, 78437)) plus 1% NP-
40. After removal of remaining large tissue particles by flowing through the Pierce Tissue 
Strainer (Thermo, 87791), the homogenized tissue was sequentially extracted using the following 
step-wise instructions: (1) Re-suspend the tissue and incubate at 4°C on rotator for 10 min 
followed by centrifugation at 4,000 g for 5 min. Save the supernatant as “NP-40 extract”. Repeat 
to wash the pellet; (2) Re-suspend the pellet in 250 μl IP buffer plus 0.1% sodium deoxycholate 
(DOC) and incubate at 4°C on rotator for 30 min followed by centrifugation at 6,000 g for 5 min. 
Save the supernatant as “DOC extract”. Repeat to wash the pellet; (3) Re-suspend the pellet in 
200 μl IP buffer plus 5 mM CaCl2 and 3,000 units/ml micrococcal nuclease (Thermo, 88216) and 
incubate at room temperature for 30 min followed by centrifugation at 16,000 g for 5 min. Save 
the supernatant as “DNase extract”. Repeat to wash the pellet; (4) Re-suspend the pellet in 150 μl 
IP buffer plus 1% SDS and incubate at room temperature for 10 min followed by centrifugation 
at 16,000 g for 5 min. Keep the supernatant as “SDS extract”. This is the fraction of 
cytoskeleton. For the extractions with TGM2 inhibition, 100 μg/ml or 500 μg/ml ERW1041E 
(Sigma, 509522) or equivalent volume of DMSO was included in every extraction buffer. 
Protein concentration was measured using a protein assay kit (BioRad, 5000112) and 1 μg of 
each fraction were boiled in Laemmli sample buffer containing 20 mM DTT, and applied to 
SDS-PAGE gel for western blot.  
Immunoprecipitation of CXCL12-KRT19 coating 
SDS in the cytoskeleton fraction was removed with the Pierce Detergent Removal Spin Column 
(Thermo, 87777). For immunoprecipitation, 100 μg of the protein extract was diluted in 500 μl 
IP buffer containing 1% BSA (Calbiochem, 2930) and 0.1% SDS which helps to prevent self-
assembly of cytokeratin proteins. The mixture was pre-cleared by centrifugation at 16,000 g for 
10 min and the supernatant was transferred in to a new tube. Then, 5 μg Rabbit isotype IgG 
(Thermo, 10500C) or Rabbit anti-CXCL12 antibody (LSBio, LS-C48888) was added in to the 
solution and incubated on rotor at 4°C overnight. Separately, 100 ul protein G agarose beads 
(Cell signaling, 37478, 50% slurry) were pre-blocked in IP buffer containing 1% BSA. After 
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overnight incubation, 20 μl pure protein G resins (or 40 μl 50% slurry) were added directly to the 
protein/antibody solution and incubated for another 2 hours at 4°C. Following three washes with 
IP buffer containing 0.1% SDS, the resins were boiled in 100 μl Laemmli sample buffer 
containing 20 mM DTT, and 10 μl of each sample was applied to SDS-PAGE gel for western 
blot where Veriblot for IP detection reagent HRP (Abcam, ab131366) was used.  
Protein Binding Assays and Cross-linking 
The buffer of commercially available recombinant human KRT19 protein (Creative Biomart, 
KRT19-7239H) was changed to protein binding buffer (25 mM Tris, pH 7.5, 100 mM NaCl, 1% 
Triton X-100), using Zeba spin desalting columns (Thermo, 89882). For protein binding, 
biotinylated recombinant human CXCL12 (Chemotactics, B-CXCL12) or CXCL8 
(Chemotactics, B-CXCL8) was incubated with KRT19 at 4°C for 2 hours. Then, streptavidin 
conjugated Dynabeads (Thermo, 11205D), pre-blocked with 1% BSA, were added and incubated 
for another 2 hours at 4°C. Following three washes, bound proteins were boiled in Laemmli 
sample buffer containing 20 mM DTT for western blotting. To measure the binding affinity 
between CXCL12 and KRT19, 100 ng CXCL12-biotin bound on streptavidin Dynabeads was 
incubated with 0, 8 nM, 16 nM, 31 nM, 63 nM, 125 nM or 250 nM KRT19 at 4°C for 4 hours. 
For TGM2 binding, KRT19 or KRT19/CXCL12 (R&D Systems, 350-NS) complex was firstly 
immobilized on protein G Dynabeads (Thermo, 10004D) via anti-KRT19 antibody (Abcam, 
ab76539). Alternatively, CXCL12-biotin or KRT19/CXCL12-biotin complex was immobilized 
on streptavidin Dynabeads. Then, recombinant human TGM2 (R&D Systems, 4376-TG-050) 
was added and incubated in the presence or absence of 10 mM CaCl2 on ice for 10 minutes. 
Following one or two quick washes on ice, with calcium containing binding buffer, bound 
proteins were boiled for western blotting.  
 
To do KRT19-CXCL12 cross-linking, 100 ng CXCL12-biotin and 500 ng KRT19 was incubated 
and bound on streptavidin Dynabeads. After three washes, KRT19/CXCL12-biotin complex 
bound Dynabeads were re-suspended in 50 μl TGM2 activation buffer (100 mM Tris, pH 7.5, 
150 mM NaCl, 10 mM CaCl2, 10 mM DTT). Then, 50 ng recombinant human TGM2, together 
with or without 100 μM ERW1041E, was added and incubated at room temperature for 15 
minutes. The reactions were stopped by direct boiling in Laemmli sample buffer containing 20 
mM DTT. 
Animals 
C57BL/6 mice of 6 weeks age were purchased from The Jackson Laboratory. After receiving, 
the mice were housed in a helicobacter free room for 2 weeks before each experiment. CD45.1 
OT-I mice were generated by cross-breeding OT-I mice (Jackson, 003831) and B6.SJL mice 
(Jackson, 002014). TGM2-KO mice were obtained by cross-breeding Tgm2-floxed mice 
(Jackson, 024694) to transgenic CMV-Cre mice (Jackson, 006054). The progeny were genotyped 
at Transnetyx for double-allele knockouts. All animal experiments were approved by the Cold 
Spring Harbor Laboratory (CSHL) Institutional Animal Care and Use Committee (IACUC) in 
concordance with the NIH “Guide for the Care and Use of Laboratory Animals”. 
CRISPR Editing and Lentivirus 
The control CRISPR guide (sgScramble: GCTTAGTTACGCGTGGACGA (13)) and the guides 
targeted to mouse Krt19 gene (sgKRT19-1: CACAGGAAATTACTGCCCTG; sgKRT19-2: 
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TAGTGGTTGTAATCTCGGGA; sgKRT19-3: CGGAGGACGAGGTCACGAAG) or mouse 
Tgm2 gene (sgTGM2-1: GAATATGTCCTTACGCAACA; sgTGM2-2: 
GTCCTGTTGGTCCAGCACTG; sgTGM2-3: TTGACCTCGGCAAACACGAA) were cloned 
into the lentiCRISPR-v2 plasmid (Addgene, 52961) and sequencing validated. The lentivirus 
was produced by co-transfecting HEK293T cells with the guide containing lentiCRISPR-v2 
plasmid together with the lentivirus packing plasmid psPAX2 (Addgene, 12260) and the envelop 
expressing plasmid pMD2.G (Addgene, 12259). 
Cancer Cell Lines 
Mouse pancreas ductal adenocarcinoma (PDA) cancer cell lines 1242 and mM1 which were 
derived from KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre) mouse tumor (14) were a gift 
from the laboratory of Dr. Tuveson. To generate sgScramble, sgKRT19 and sgTGM2 cell lines, 
1242 cells were transduced with lentivirus expressing SpCas9 and specific CRISPR guides. The 
transduced cells were directly selected with 1 μg/ml puromycin (Sigma, P8833) for polyclonal 
stable cell lines. The single cell clones were generated by limited dilution. To rescue KRT19 
expression in the Krt19-edited cancer cells which was achieved by transduction with the 
lentivirus containing the sgKRT19-1 guide, the single cell clone was further transduced with 
lentivirus expressing mouse KRT19 with four synonymous mutations at the guide targeting site. 
To facilitate tumor imaging in vivo for hepatic metastasis, the sgScramble and sgKRT19 cell 
lines were transduced with lentiviral plasmid expressing firefly luciferase and GFP which are 
linked by 2A peptide. The luciferase/GFP transduced cells were sorted by FACS. Doxycycline-
inducible ovalbumin-expressing cells were generated by transducing mM1cells, 1242-
sgScramble cells and 1242-sgKRT19 cells with the lentiviral vector pCW57-gfp-p2a-mcs 
(Addgene, 89181) containing the cytoplasmic version of ovalbumin followed by FACS sorting 
and single cell cloning. All the cancer cell lines were cultured in DMEM medium (Cellgro, 10-
013-CV) supplemented with 10% FBS (Seradigm, 1500-500), 100 units/ml penicillin and 100 
μg/ml streptomycin. 
Mouse Studies 
For subcutaneous tumors, 2.5×105 cells, unless indicated otherwise, were injected into the right 
flank of mice. Tumor volume was measured with caliper every two or three days and calculated 
according to the formula V = (L×W2)/2. Mice that were developing tumor associated skin ulcer 
during the experiment were humanely sacrificed, and the visually ulcerated tumors were not 
included in further analysis. For the hepatic metastasis model, 2.5×104 or 1.0×105 luciferase 
expressing cells were injected into the portal vein. Tumor size was monitored through 
bioluminescence imaging every 3 or 4 days. To do so, 150 μl of 30 mg/ml D-Luciferin (Perkin-
Elmer, 122799-10) was administered through intraperitoneal injection and mice were imaged 
with the IVIS Spectrum in vivo Imaging System. For mouse tumor immunotherapy, 200 μg 
isotype IgG (BioXcell, BP0089) or Rat anti-mouse PD-1 antibody (BioXcell, BP0273) was given 
through intraperitoneal injection on indicated days. T cell depletion was achieved by 
intraperitoneal injection of 200 μg anti-CD4 (BioXcell, BP0003) and anti-CD8 (BioXcell, 
BP0061) antibodies twice a week. Mice that were developing tumor associated ascites or 
lethargy during the experiment were humanely sacrificed. 
 
As to the ovalbumin inducible hepatic metastasis model, 1000 CD45.1 OT-I CD8+ cells, isolated 
from the spleen of CD45.1 OT-I mouse using CD8a+ T cell isolation kit (Miltenyi Biotec, 130-
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104-075), were injected into C57BL/6J mice intravenously prior to cancer cell injection via the 
portal vein. Doxycycline induction of ovalbumin was 11 days after cancer cell injection (5×104 
cells), using doxycycline food, and the metastatic tumors were harvest 7 days later. For the 
ovalbumin inducible 1242-sgScramble and 1242-sgKRT19 subcutaneous tumors, 5×105 cells 
were inoculated and ovalbumin was induced at day 0. 
Immunofluorescence  
Mouse tumors were embedded in Tissue-Tek OCT compound (Sakura, 4583) and freshly frozen 
on dry ice. In the case of hepatic metastatic tumors, the whole livers were perfused through the 
portal vein with cold PBS before freezing. The embedded tumors were sectioned at 10 μm for 
staining. For Human FFPE tumor arrays, the slides were deparaffinized in Xylene for three times 
(5 min each) followed by sequential rehydration treatments in 100% ethanol (5 min, 3 times), 
95% ethanol (10 min, twice), 70% ethanol (10 min, twice), 50% ethanol (10 min, twice), and 
water (5 min, twice). After rehydration, antigen retrieval was conducted by boiling the sample in 
10 mM Tris-HCl (pH 8.8) plus 1 mM EDTA for 10 min, followed by cooling down to room 
temperature for 30 min and subsequent two washes in water for 5 min each.  
 
To stain tumor sections, the samples were fixed with freshly prepared PLP buffer (100 mM 
phosphate buffer, pH 7.4, 80 mM L-lysine, 10 mM NaIO4, and 4% paraformaldehyde) for 10 
min at room temperature. After washing with PBS, a hydrophobic barrier was drawn around the 
tumor slice with ImmEdge PAP pen (Vector Laboratories, H-4000). The sections were then 
permeabilized with 0.2% TritonX-100 in PBS for 15 min followed by blocking with 1% BSA 
(Calbiochem, 2930) plus 10% normal goat serum (Thermo, 16210064) in PBS at room 
temperature for 1 hour. After the blocking, the tumor slices were stained by incubation with non-
conjugated primary antibodies (Table S1) at 4°C overnight, and subsequently with fluorophore 
conjugated secondary antibodies at room temperature for 1 hour. When fluorophore conjugated 
primary antibodies (Table S1) were used, the sections were incubated with the antibodies at 
room temperature for 2 hours. Nuclei were stained with DAPI (Thermo, R37606) at room 
temperature for 10 min. In between each steps, sections were washed twice with 0.05% Tween-
20 in PBS and once with PBS for 5 min for each wash. After the stainings, tumor sections were 
mounted with mounting medium (Thermo, P36961). For the staining of the thick (30 μm) non-
permeabilized section, TritonX-100 was not included. Images were acquired on Leica SP8 
confocal microscope or ZEISS Observer microscope and analyzed with ImageJ software. 
RNA FISH 
RNA FISH was done with fresh frozen tumor samples according to user manual of RNAScope 
Fluorescent Multiplex Reagent kit (ACDBio, 320850). RNAScope probes for mouse Cxcl12 
(422711), Pdgfra (480661-C2), and Krt19 (402941-C3) were used in this study. Images were 
acquired on Leica SP8 confocal microscope and analyzed with ImageJ. 
Flow Cytometry 
Freshly resected tumors were minced and digested in complete DMEM cell culture medium 
containing 250 μg/ml Collagenase D (Sigma, 11088858001), 50 μg/ml Liberase DL (Sigma, 
05466202001) and 20 μg/ml DNase I (Sigma, 10104159001) at 37°C for 45 min, shaking. 
Following lysis of red blood cells in RBC lysis buffer (155 mM NH4Cl, 12 mM NaHCO3 and 0.1 
mM EDTA), cells were passed through 70 μm cell strainer and re-suspend in DMEM medium 
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containing 50 μg/ml DNase I to digest released DNA from RBC cells. After incubation at room 
temperature for 15 min, the cells were washed and re-suspended in FACS buffer (PBS, 2% FBS 
and 20 mM HEPES, pH 7.4). For staining, the cells were firstly blocked with Rat anti-mouse 
CD16/CD32 antibody (BioLegend, 101302) in FACS buffer, shaking at 4°C for 30 min. Then, 
fluorophore conjugated antibodies (Table S1) were added and incubated for another 30 min in 
the dark, followed by two washes with FACS buffer. Calcein violet 450 AM (Thermo, 65-0854-
39) or DAPI (Thermo, R37606) was used for live cell gating. Data were acquired using a BD 
LSRForsseta cell analyzer equipped with Diva software 6.0 and were further analyzed with 
FlowJo. 
qPCR 
Tumor samples of about 30 mg were flash-frozen in liquid nitrogen and stored in -80°C. Total 
RNA was extracted with RNeasy mini kit (Qiagen, 74106) according to the manual. To make the 
cDNA library, 1 μg total RNA was reverse transcribed with Taqman Reverse Transcription Kit 
(Thermo, N8080234), using oligo d(T)s. The cDNA library was then diluted in 100 μl nuclease 
free water. For qPCR, 5 μl diluted cDNA library was mixed in 384-well plate with specific 
Taqman probes (Table S2) and Taqman Universal Master Mix II (Thermo, 4440040) to make 10 
μl reaction volumes. The qPCRs were run in QuantStudio 6. All the gene expression values were 
normalized to Tbp. 
RNA-Seq 
Subcutaneous tumors were harvest two weeks post cancer cell inoculation. The sequencing 
libraries were prepared according to Illumina TruSeq Stranded Total RNA Sample Preparation 
Guide, with certain modifications. Briefly, 4 μg total RNA of each sample was used to make the 
cDNA library. To enrich DNA fragments at the final step, 12 PCR cycles, instead of 15, was 
adopted. For library pooling, each cDNA library was diluted to 10 nM and 30 μl of each sample 
was pooled. The final pooled library was submitted to CSHL Sequencing Core for high-out next 
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Figure S1: The characterization of the CXCL12-KRT19 coating of human 
adenocarcinomas. (A-B) Sections of FFPE human carcinomas and melanoma (A) and frozen 
human carcinomas (B) were stained with fluorescent antibodies to KRT19 and CXCL12. Scale 
bars, 100 μm. (C) The NP-40 eluates of the four human tumors (Fig. 1A) were subjected to SDS-
PAGE and immunoblotting with anti-CXCL12 or anti-KRT19 antibodies. The SDS eluate of 
patient 2 was applied as a positive control. 
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Figure S2: Characterization of the CXCL12-KRT19 coating of mouse PDA tumors. (A) A 
frozen section of mouse autochthonous KPC tumor was stained with fluorescent antibodies to 
KRT19 and CXCL12. Scale bar, 100 μm. (B) Sequential detergent eluates of a mouse 
subcutaneous PDA were subjected to SDS-PAGE and immunoblotting with anti-KRT19 or anti-
CXCL12 antibody. (C) The proteins that were immunoprecipitated by control IgG or anti-
CXCL12 antibody from the SDS-eluate of a mouse subcutaneous PDA were subjected to SDS-
PAGE and immunoblotting with anti-CXCL12 or anti-KRT19 antibodies. (D) The mRNAs of 
Cxcl12, Pdgfra (indicating CAFs) and Krt19 (PDA cells) were detected by RNA fluorescent in 
situ hybridization (FISH) in sections of a mouse subcutaneous PDA. The pie chart shows relative 
proportions of the cells that are Pdgfra+, or Cxcl12+ or double positive. Scale bar, 50 μm. (E) 30 
μm-thick sections of a mouse subcutaneous PDA were permeabilized with Triton X-100, or not, 
were stained with fluorescent antibodies to KRT19, CXCL12, and tubulin. Scale bars, 10 μm. 
(F) Intact, DAPI-excluding dissociated cells from a mouse subcutaneous PDA tumor that had 
been stained with fluorescent antibodies to CXCL12, KRT19 and CD45, were assessed by flow 
cytometry.  
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Figure S3: The interactions among CXCL12, KRT19, and TGM2. (A) In the experiment 
depicted in Fig. 1D, KRT19 bound to CXCL12 was measured by immunoblot analysis of the 
eluates of streptavidin beads. (B) Biotinylated human CXCL8 or CXCL12 that was immobilized 
on streptavidin beads was incubated with KRT19, and bound proteins were subjected to SDS-
PAGE and blotting with streptavidin-HRP or anti-KRT19 antibody. (C) CXCL12-biotin or the 
preformed CXCL12-biotin/KRT19 complex that was immobilized on streptavidin beads was 
incubated with TGM2, and bound proteins were subjected to SDS-PAGE and blotting with 
streptavidin-HRP, anti-KRT19, and anti-TGM2, as indicated.  (D) Sequential extractions of 
mouse subcutaneous PDA were performed in the presence of 100 μg/ml, 500 μg/ml ERW1041E, 
or DMSO, and the SDS eluates were analyzed by SDS-PAGE and immunoblotting with anti-
CXCL12 or anti-KRT19 antibodies. 
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Figure S4: Tgm2-edited PDA cells and the formation of the CXCL12-KRT19 coating. (A) 
Lysates from mouse PDA cell lines that were CRISPR/Cas9 edited with scramble sgRNA or 
three different Tgm2 sgRNAs were subjected to SDS-PAGE and immunoblotting with anti-
TGM2, anti-KRT19 or anti-actin antibodies. (B) In vitro growth of sgScramble and sgTGM2-
edited PDA cells was assessed by staining every 12 hours with crystal violet. (C) Tissue sections 
of subcutaneous tumors formed by control and the three Tgm2-edited PDA cell lines were 
stained with fluorescent antibodies to KRT19 and CXCL12, respectively. Scale bar, 100 μm. 
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Figure S5: The role of TGM2 expression by mouse PDA cells in the formation of the 
CXCL12-KRT19 coating. (A) SDS eluates of subcutaneous tumors formed with sgScramble or 
sgTGM2-edited PDA cells in wild-type hosts were subjected to SDS-PAGE and immunoblotting 
with anti-CXCL12 or anti-KRT19 antibodies. (B) Sections of subcutaneous tumors formed with 
sgScramble or sgTGM2-edited PDA cell lines, in wild-type hosts or TGM2-KO hosts, were 
stained with fluorescent anti-KRT19 and anti-FXIIIa antibodies. (C) mRNA levels of members 
of the transglutaminase family in mouse PDA cancer cell organoids are shown (11). (D) 
Subcutaneous tumors formed with sgScramble or sgTGM2-edited PDA cell lines, in wild-type 
hosts or TGM2-KO hosts, were stained with fluorescent anti-KRT19 and anti-TGM2 antibodies. 
Scale bars, 100 µm. 
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Figure S6: Krt19-edited PDA cells and the formation of the CXCL12-KRT19 coating. (A) 
Lysates from mouse PDA cell lines that were CRISPR/Cas9 edited with scramble sgRNA or 
three different Krt19 sgRNAs were subjected to SDS-PAGE and immunoblotting with anti-
KRT19 or anti-actin antibodies. (B) Crystal violet stains measuring the in vitro growth of 
sgScramble and sgKRT19-edited PDA cells are shown. (C) Tissue sections of subcutaneous 
tumors formed by control and the three Krt19-edited PDA cell lines were stained with 
fluorescent antibodies to KRT20 to reveal cancer cells, KRT19 and CXCL12, respectively.  (D) 
Sections of subcutaneous tumors formed with sgScramble-, sgKRT18- or sgKRT19-edited PDA 
cells were stained with fluorescent antibodies to KRT8, KRT18, KRT19, KRT20 and CXCL12, 
respectively. Scale bars, 100 μm. 
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Figure S7: Rescue of KRT19 expression in Krt19-edited PDA cells. (A) Sequencing of the 
KRT19 rescue construct where four synonymous mutations, shown in black boxes, were 
introduced to prevent the binding of sgKRT19-1. (B) PDA cell lysates were subjected to SDS-
PAGE and immunoblotting with anti-KRT19 and anti-actin antibodies. (C) Tissue sections of 
subcutaneous tumors formed with the sgScramble PDA cells, sgKRT19-edited PDA cells, and 
the KRT19-rescue PDA cells were stained with fluorescent antibodies to KRT20 to reveal cancer 
cells, KRT19, CXCL12, and CD3, respectively. Scale bars, 100 μm. 
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Figure S8: The CXCL12-KRT19 coating of cancer cells in MSS and MSI-Hi PDA and in 
mouse hepatic PDA metastases.  (A-B) Sections of FFPE human MSS and MSI-Hi PDA were 
stained with fluorescent antibodies to KRT19 and CXCL12. (C) Sections of mouse hepatic PDA 
metastases formed without and with Dox-induced OVA expression were stained with fluorescent 
antibodies to KRT19, CXCL12, and CD45.1. The CD45.1+ OT-I cells were adoptively 
transferred to mice before the intra-portal injection of the PDA cells. Scale bars, 100 μm. 
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Figure S9: Development of neutralizing anti-rat antibodies in mice receiving rat anti-mouse 
PD-1 antibody. Mouse anti-rat IgG in blood serum of mice receiving rat anti-mouse PD-1 
antibody was measured by means of ELISA. 200 μg rat anti-mouse PD-1 antibody was 
administered by intra-peritoneal injections at indicated days (red arrows). 
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Figure S10: Gene expression analysis of the subcutaneous PDA tumors treated with anti-
PD-1 antibody. PDA-bearing mice were treated with 200 μg isotype IgG or anti-PD-1 antibody 
at day 13 and day 15 after cancer cell inoculation. Mice were sacrificed at day17, and samples of 
the tumors were obtained. The mRNA levels of each gene in the tumor samples were measured 
by qPCR. Expression of each gene in sgScramble tumors from mice that had been treated with 
isotype IgG were normalized to 1. Mean ± SEM; * p<0.05, ** p<0.01, Student’s t test. 
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Figure S11: Characterization of Krt19-edited mouse PDA hepatic metastases. (A-C) 
Sections of the control and Krt19-edited PDA metastases were stained with fluorescent 
antibodies to KRT20, KRT19, CXCL12, CD3, fibroblast activation protein (FAP), and pan-
cytokertain (CK), respectively. Scale bars, 100 μm. (D) mRNAs for Cxcl12, Pdgfra and Krt19 
were detected by RNA FISH in sections of hepatic metastases. The pie chart shows the relative 
proportions of the cells that are Pdgfra+, or Cxcl12+ or double positive. Scale bar, 50 μm. 
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Figure S12: Bioluminescent images of hepatic metastases formed with luciferase-expressing 
control and Krt19-edited PDA cells.  (A) Hepatic metastases were formed by injecting 2.5×104 
Krt19-edited PDA cells into the portal vein at day 0 in mice that had been pre-treated with non-
immune IgG or depleting antibodies to CD4 and CD8, and growth of the metastases was 
measured by bioluminescent imaging. (B-C) Representative bioluminescence images of the mice 
in which metastasis growth was depicted in Fig. 4B. 
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Figure S13: Expression of immune genes in hepatic metastases formed with control 
(sgScramble) and Krt19-edited (sgKRT19) PDA cells. The mRNA levels were measured by 
qPCR and expression of each gene was normalized to that of the control levels, which were 
assigned a value of 1. Mean ± SEM; ** p<0.01, Student’s t test. 
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Table S1: Primary antibody list 
Antibody Vendor Catalog NO. Reactivity Application 
KRT19-AF568 Abcam ab203445 Hs, Mm IF, FC 
KRT19-AF647 Abcam ab192980 Hs, Mm IF, FC 
KRT8-AF647 Abcam ab192468 Mm IF 
CXCL12-FITC R&D IC350F Hs, Mm IF (Frozen), FC 
Melan-A-AF647 NOVUS NBP2-46603AF647 Hs IF 
CD45-BV510 BioLegend 103138 Mm FC 
CD3-AF647 BioLegend 100209 Mm IF 
Tubulin-AF488 Cell Signaling 36234S Mm IF 
panCK-AF647 NOVUS NBP1-48348AF647 Mm IF 
Mm-anti-CXCL12 R&D MAB350 Hs, Mm IF (FFPE) 
Rb-anti-CXCL12 Peprotech 500-P87A Hs, Mm IF (FFPE), WB 
Rb-anti-CXCL12  LSBio  LS-C48888 Hs, Mm IP 
Rb-anti-KRT19 Abcam ab76539 Hs IP 
Rb-anti-KRT19 Abcam ab52625 Hs, Mm IF, WB 
Rt-anti-KRT19 DHSB TROMA-III Mm WB 
Rb-anti-KRT20 Abcam ab230524 Mm IF 
Mm-anti-KRT18  Abcam  ab668 Mm IF, WB 
Rb-anti-KRT8 Abcam ab53280 Mm IF, WB 
Sh-anti-TGM2 R&D AF5418 Mm IF, WB 
Mm-anti-FXIIIa Abcam ab1834 Mm IF 
Rb-anti-Actin Abcam ab8227 Mm WB 
Rb-anti-FAP Millipore ABT11 Mm IF 
Mm-anti-CD45.1 BioLegend 110702 Mm IF 
Rt-anti-CD3 BioLegend 100202 Mm IF 
Rt-anti-CD8 BioXcell BP0061 Mm T cell Depletion 
Rt-anti-CD4 BioXcell BP0003 Mm T cell Depletion 
Rt-anti-PD-1 BioXcell BP0273 Mm PD-1 blocking 
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Table S2: Taqman probes for qPCR (Thermo) 
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